362 related articles for article (PubMed ID: 10759015)
1. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
3. Immunoaffinity purification of factor VIII.
Weinstein RE
Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
[TBL] [Abstract][Full Text] [Related]
4. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
5. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
6. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
7. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
Smith KJ; Lusher JM; Cohen AR; Salzman P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
9. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
[TBL] [Abstract][Full Text] [Related]
10. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
[TBL] [Abstract][Full Text] [Related]
13. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
15. Human parvovirus PARV4 in clotting factor VIII concentrates.
Fryer JF; Hubbard AR; Baylis SA
Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
[TBL] [Abstract][Full Text] [Related]
16. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
17. Pathogen safety of Beriate®.
Gröner A
Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
[TBL] [Abstract][Full Text] [Related]
18. Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate.
Hart H; Jones A; Cubie H; McIntosh RV; Cuthbertson B
Vox Sang; 1994; 67 Suppl 1():51-5. PubMed ID: 8091738
[TBL] [Abstract][Full Text] [Related]
19. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
